Telomir Pharmaceuticals' Telomir-Zn Approved by FDA
Telomir Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has cleared the Company's Investigational New Drug, IND, application for its lead candidate, Telomir-Zn, for the treatment of patients with advanced or metastatic triple-negative breast cancer, TNBC.
Trade with 70% Backtested Accuracy
Analyst Views on TELO
About TELO
About the author
Telomir Pharmaceuticals Receives FDA Approval for Clinical Trial
- FDA IND Approval: Telomir Pharmaceuticals has received FDA clearance for its lead candidate Telomir-Zn, marking a significant step toward clinical evaluation aimed at addressing the urgent needs of patients with advanced triple-negative breast cancer.
- Clinical Trial Design: The planned Phase 1/2 trial, set to initiate in the first half of 2026, will enroll approximately 76 patients using a 3+3 dose escalation design to evaluate the safety, tolerability, and preliminary antitumor activity of Telomir-Zn.
- Biomarker Analysis: The study will incorporate an integrated biomarker program to assess changes in epigenetic regulation and their correlation with clinical outcomes, aiming to identify potential predictive biomarkers to guide future treatment strategies.
- Significant Market Potential: Triple-negative breast cancer accounts for 10-15% of breast cancer cases, and despite limited existing treatment options, the global market presents a multi-billion-dollar opportunity, with Telomir-Zn's development poised to fill this gap.
Telomir Pharmaceuticals Submits IND for TNBC Treatment
- IND Submission: Telomir Pharmaceuticals has submitted an Investigational New Drug application to the FDA for its lead candidate, Telomir-1, targeting advanced and metastatic Triple-Negative Breast Cancer (TNBC), marking a critical transition from preclinical proof-of-concept to clinical development.
- Clinical Trial Plan: Subject to IND clearance, the company plans to initiate a Phase 1/2 clinical trial to evaluate Telomir-1 as an oral monotherapy, utilizing a standard 3+3 dose-escalation design to assess safety and preliminary antitumor activity, focusing on determining the recommended Phase 2 dose.
- Preclinical Findings: Telomir-Zn demonstrated significant tumor growth reduction and decreased metastatic dissemination across various TNBC models, showing iron-dependent tumor cell mortality in chemotherapy-resistant settings, indicating its potential efficacy in treatment.
- Market Opportunity: Triple-Negative Breast Cancer accounts for 10-15% of all breast cancer cases, with limited treatment options available, creating a substantial unmet need for more effective and durable therapies, and the successful development of Telomir-Zn could significantly improve patient outcomes and reshape the treatment landscape.
Coinbase CEO Armstrong Invests in NewLimit, Secures $45 Million Funding
- Company Formation: Coinbase CEO Brian Armstrong's startup NewLimit, founded in 2021, focuses on extending human healthspan by treating age-related diseases, with its latest funding round of $45 million boosting its valuation to $1.62 billion, indicating strong market interest in anti-aging technologies.
- Funding Context: The rapid follow-up funding just five months after its Series B round demonstrates NewLimit's swift growth and investor confidence in the anti-aging sector, with the new capital expected to lay the groundwork for future clinical studies that could advance its technological capabilities.
- Intensifying Competition: With OpenAI CEO Sam Altman investing $180 million in Retro Biosciences, the race to develop technologies that extend human lifespan is heating up, reflecting significant market attention and potential economic returns in this burgeoning field.
- Market Reaction: Despite a downturn in anti-aging research stocks in 2025, NewLimit's successful funding round showcases investor confidence in its long-term potential, which may attract further capital into this emerging market.
Friday's Underperformers: Pharmaceutical, Oil, and Gas Exploration & Production Shares
Market Performance: Oil and gas exploration and production shares are down approximately 1.6%, with Venture Global experiencing a significant drop of about 19.6% and Amplify Energy down by about 5.5%.
Sector Laggards: The decline in oil and gas stocks is highlighted as part of the broader market trends, alongside other sectors such as pharmaceuticals.
Stock Market Update: Dow Jones and Nasdaq Futures Decline as Trade Deficit Data Release is Postponed Due to Shutdown—Trilogy Metals, AMD, and Applovin Under Scrutiny
U.S. Stock Market Update: U.S. stock futures declined following a mixed performance on Monday, with major indices showing slight decreases. The market is influenced by a deal between Advanced Micro Devices and OpenAI, which boosted AI-related stocks.
Government Shutdown Impact: The ongoing government shutdown has delayed the release of U.S. trade deficit data, with President Trump indicating a willingness to collaborate with Democrats on healthcare only after the government reopens.
Key Stock Movements: Trilogy Metals surged 180.38% after a White House investment announcement, while Applovin fell 2.56% amid an SEC investigation. Advanced Micro Devices rose 2.57% due to its deal with OpenAI, and Telomir Pharmaceuticals jumped 30.99% following positive study results.
Economic Outlook: Analysts predict a strong earnings season for Q3 2025, with expectations of low-teens earnings growth for the S&P 500, driven by AI investments and a resilient economy, despite potential tariff pressures.
TELO, PCSA, RVPH, NMTC, BRTX Experience After-Hours Trading Surge Amid Limited News and Specific Updates
Biotech Stock Gains: Small-cap biotech stocks TELO, PCSA, RVPH, NMTC, and BRTX experienced significant after-hours gains driven by speculative trading and company updates, despite the absence of new disclosures.
Telomir Pharmaceuticals (TELO): TELO shares surged 43% after-hours, attributed to renewed interest in its in vitro data showcasing Telomir-1's unique targeting capabilities in cancer therapies.
Processa Pharmaceuticals (PCSA): PCSA shares rose 32.6% in after-hours trading, continuing a rally from the regular session, with no recent official news or updates from the company.
NeuroOne Medical Technologies (NMTC): NMTC shares increased 9.5% after announcing a 163% rise in preliminary product revenue for fiscal year 2025, alongside an upcoming virtual webinar, which sparked investor interest.
Telomir Pharmaceuticals Receives FDA Approval for Clinical Trial
- FDA IND Approval: Telomir Pharmaceuticals has received FDA clearance for its lead candidate Telomir-Zn, marking a significant step toward clinical evaluation aimed at addressing the urgent needs of patients with advanced triple-negative breast cancer.
- Clinical Trial Design: The planned Phase 1/2 trial, set to initiate in the first half of 2026, will enroll approximately 76 patients using a 3+3 dose escalation design to evaluate the safety, tolerability, and preliminary antitumor activity of Telomir-Zn.
- Biomarker Analysis: The study will incorporate an integrated biomarker program to assess changes in epigenetic regulation and their correlation with clinical outcomes, aiming to identify potential predictive biomarkers to guide future treatment strategies.
- Significant Market Potential: Triple-negative breast cancer accounts for 10-15% of breast cancer cases, and despite limited existing treatment options, the global market presents a multi-billion-dollar opportunity, with Telomir-Zn's development poised to fill this gap.
Telomir Pharmaceuticals Submits IND for TNBC Treatment
- IND Submission: Telomir Pharmaceuticals has submitted an Investigational New Drug application to the FDA for its lead candidate, Telomir-1, targeting advanced and metastatic Triple-Negative Breast Cancer (TNBC), marking a critical transition from preclinical proof-of-concept to clinical development.
- Clinical Trial Plan: Subject to IND clearance, the company plans to initiate a Phase 1/2 clinical trial to evaluate Telomir-1 as an oral monotherapy, utilizing a standard 3+3 dose-escalation design to assess safety and preliminary antitumor activity, focusing on determining the recommended Phase 2 dose.
- Preclinical Findings: Telomir-Zn demonstrated significant tumor growth reduction and decreased metastatic dissemination across various TNBC models, showing iron-dependent tumor cell mortality in chemotherapy-resistant settings, indicating its potential efficacy in treatment.
- Market Opportunity: Triple-Negative Breast Cancer accounts for 10-15% of all breast cancer cases, with limited treatment options available, creating a substantial unmet need for more effective and durable therapies, and the successful development of Telomir-Zn could significantly improve patient outcomes and reshape the treatment landscape.
Coinbase CEO Armstrong Invests in NewLimit, Secures $45 Million Funding
- Company Formation: Coinbase CEO Brian Armstrong's startup NewLimit, founded in 2021, focuses on extending human healthspan by treating age-related diseases, with its latest funding round of $45 million boosting its valuation to $1.62 billion, indicating strong market interest in anti-aging technologies.
- Funding Context: The rapid follow-up funding just five months after its Series B round demonstrates NewLimit's swift growth and investor confidence in the anti-aging sector, with the new capital expected to lay the groundwork for future clinical studies that could advance its technological capabilities.
- Intensifying Competition: With OpenAI CEO Sam Altman investing $180 million in Retro Biosciences, the race to develop technologies that extend human lifespan is heating up, reflecting significant market attention and potential economic returns in this burgeoning field.
- Market Reaction: Despite a downturn in anti-aging research stocks in 2025, NewLimit's successful funding round showcases investor confidence in its long-term potential, which may attract further capital into this emerging market.
Friday's Underperformers: Pharmaceutical, Oil, and Gas Exploration & Production Shares
Market Performance: Oil and gas exploration and production shares are down approximately 1.6%, with Venture Global experiencing a significant drop of about 19.6% and Amplify Energy down by about 5.5%.
Sector Laggards: The decline in oil and gas stocks is highlighted as part of the broader market trends, alongside other sectors such as pharmaceuticals.
Stock Market Update: Dow Jones and Nasdaq Futures Decline as Trade Deficit Data Release is Postponed Due to Shutdown—Trilogy Metals, AMD, and Applovin Under Scrutiny
U.S. Stock Market Update: U.S. stock futures declined following a mixed performance on Monday, with major indices showing slight decreases. The market is influenced by a deal between Advanced Micro Devices and OpenAI, which boosted AI-related stocks.
Government Shutdown Impact: The ongoing government shutdown has delayed the release of U.S. trade deficit data, with President Trump indicating a willingness to collaborate with Democrats on healthcare only after the government reopens.
Key Stock Movements: Trilogy Metals surged 180.38% after a White House investment announcement, while Applovin fell 2.56% amid an SEC investigation. Advanced Micro Devices rose 2.57% due to its deal with OpenAI, and Telomir Pharmaceuticals jumped 30.99% following positive study results.
Economic Outlook: Analysts predict a strong earnings season for Q3 2025, with expectations of low-teens earnings growth for the S&P 500, driven by AI investments and a resilient economy, despite potential tariff pressures.
TELO, PCSA, RVPH, NMTC, BRTX Experience After-Hours Trading Surge Amid Limited News and Specific Updates
Biotech Stock Gains: Small-cap biotech stocks TELO, PCSA, RVPH, NMTC, and BRTX experienced significant after-hours gains driven by speculative trading and company updates, despite the absence of new disclosures.
Telomir Pharmaceuticals (TELO): TELO shares surged 43% after-hours, attributed to renewed interest in its in vitro data showcasing Telomir-1's unique targeting capabilities in cancer therapies.
Processa Pharmaceuticals (PCSA): PCSA shares rose 32.6% in after-hours trading, continuing a rally from the regular session, with no recent official news or updates from the company.
NeuroOne Medical Technologies (NMTC): NMTC shares increased 9.5% after announcing a 163% rise in preliminary product revenue for fiscal year 2025, alongside an upcoming virtual webinar, which sparked investor interest.
